<DOC>
	<DOCNO>NCT02015481</DOCNO>
	<brief_summary>The Purpose study ass Safety , Tolerability Efficacy Intravenous Cabaletta® Oculopharyngeal Muscular Dystrophy ( OPMD ) Patients .</brief_summary>
	<brief_title>Safety Tolerability Efficacy Study Cabaletta Treat Oculopharyngeal Muscular Dystrophy ( OPMD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Oculopharyngeal</mesh_term>
	<criteria>Males females 18 80 year ( inclusive ) age Clinically genetically diagnose OPMD Moderate dysphagia ( abnormal drinking test screen first dose day , drug administration ) Patients provide write informed consent participate study Body Mass Index ( BMI ) &lt; 30 kg/m2 Diabetes mellitus type 1 2 Other major disease , e.g . : renal failure ( creatinine clearance &lt; 60ml/min ) , liver failure chronic liver disease ( e.g . hepatitis B C ) , HIV carrier , tuberculosis , SLE , rheumatoid polyarthritis , sarcoidosis , collagenosis Uncontrolled heart disease , CHF , Other neuromuscular disease Other disorder associate esophageal dysphagia : e.g . severe gastroesophageal reflux ( GERD ) , esophageal stricture due mechanical chemical trauma , infection ( e.g . esophageal moniliasis ) , druginduced dysphagia ( e.g . bisphosphonates ) , esophageal ring web , spastic motility disorder esophagus . History malignancy ( except noninvasive skin malignancy ) History neck irradiation Pregnant currently lactate woman Obesity ( BMI≥ 30 ) associate morbidity Prior pharyngeal myotomy Weight loss 10 % last 12 month . Known hypersensitivity ingredient injection Patient receive anticoagulant treatment ( e.g . warfarin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Case control , safety , tolerability , efficacy .</keyword>
</DOC>